Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

The initial treatment for metastatic squamous cell non-small cell lung cancer (NSCLC) consists of platinum-based combination chemotherapy. The most commonly used regimens are carboplatin and paclitaxel, carboplatin and protein-bound paclitaxel (nab-paclitaxel), and cisplatin and gemcitabine.